EAPCI General Assembly

Tuesday 25 May 2010

17:35 – 18:35
Welcome

Prof C. Di Mario, EAPCI President (UK)
EAPCI Structure

President
C. Di Mario

President Elect
J. Fajadet

Secretary
S. Windecker

Congress

Journal

Executive Board

EuroPCR Rep.
M. Noc

Treasurer
K. Niemela

EuroPCR Rep.
M. Sabate

Committees

www.escardio.org/EAPCI

www.pcronline.com
EAPCI Committees
Composition agreed with the National Societies

- July / Sept 2009: Proposals from National Interventional Societies
- Members appointment By Board & Committee Chairs
- Renewal: every 2 to 4 years
EuroPCR Program Committee
More democratic representation in selection of topics and speakers

<table>
<thead>
<tr>
<th>2008-2010</th>
<th>2010-2012</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>24 members:</strong></td>
<td><strong>20 members:</strong></td>
</tr>
<tr>
<td>Coronary: 14</td>
<td>Coronary: 12</td>
</tr>
<tr>
<td>(EAPCI made proposals, final decision EuroPCR)</td>
<td>EAPCI board 9*</td>
</tr>
<tr>
<td>EAPCI Pres. 1</td>
<td>EuroPCR board 3</td>
</tr>
<tr>
<td>EACTS 2</td>
<td>EAPCI pres. 1</td>
</tr>
<tr>
<td>Peripheral 2</td>
<td>EACTS 3</td>
</tr>
<tr>
<td>Nurses 3</td>
<td>Peripheral: 2</td>
</tr>
<tr>
<td></td>
<td>Nurses: 2</td>
</tr>
</tbody>
</table>

*: National WG Presidents or Presidents Elect, renewed for 2/3 every 2 yrs
EAPCI & National Interventional Societies: partners for the future

Prof V. Schächinger, Co-Chairman, EAPCI International Affairs and National Societies Committee (Germany)
<table>
<thead>
<tr>
<th>Event</th>
<th>Date</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tunisian Society of Cardiology, Tunis</td>
<td>December 2009</td>
<td>Prof M. Gilard</td>
</tr>
<tr>
<td>BCIS, London, UK</td>
<td>January 2010</td>
<td>Prof C. Di Mario</td>
</tr>
<tr>
<td>8th Gulf Heart Association, Quatar</td>
<td>April 2010</td>
<td>Dr J. Fajadet</td>
</tr>
<tr>
<td>32th Congress of Cardiology, Lisbon, Portugal</td>
<td>April 2010</td>
<td>Prof L. Goncalves</td>
</tr>
<tr>
<td>WCCI, Warsaw, Poland</td>
<td>April 2010</td>
<td>Dr J. Fajadet</td>
</tr>
<tr>
<td>Hungarian Society of Cardiology meeting</td>
<td>May 2010</td>
<td>Prof C. Di Mario</td>
</tr>
<tr>
<td>Association of Cardiologists of Bosnia &amp; Herzegovina, Sarajevo</td>
<td>May 2010</td>
<td>Dr M. Noc</td>
</tr>
<tr>
<td>Russian Federation</td>
<td>June 2010</td>
<td>Prof C. Di Mario</td>
</tr>
<tr>
<td>31st National Congress of the Italian Society of Invasive Cardiology (GISE), Genova</td>
<td>October 2010</td>
<td>Prof C. Di Mario</td>
</tr>
<tr>
<td>Israel Tel Aviv</td>
<td>December 2010</td>
<td>Prof C. Di Mario</td>
</tr>
</tbody>
</table>

Topic lectures = Stent for Life
Membership Evolution

Membership Evolution 2006 – 2010

- 2006: 398 members
- 2007: 1392 members
- 2008: 1857 members
- 2009: 2220 members
- April 2010: 2574 members
- Projected end 2010: 3280 members

Total number of members
Top 10 Countries - Comparison vs number of interventionalists

EAPCI Membership

- Italy: 211
- UK: 162
- Germany: 151
- Spain: 140
- Poland: 134
- Egypt: 131
- France: 126
- India: 120
- Turkey: 90
- Iran (Islamic Republic of): 86

Number of EAPCI Members
EAPCI Membership: eligibility and process

• Open to **all health** specialists whose primary interest lies in the field of cardiovascular interventions from ESC Member and non-ESC Member countries.

• Only interventionalists active in an ESC Member country and member of their National Society and/or Interventional Working Groups have voting rights.

• Free and unlimited membership

• Register
  • on ESC/EAPCI Stand T10, Hall Ternes, Level 1
  • online at www.escardio.org/EAPCI
European Certification of Interventional Training

Prof M. Gilard, Chair Training Committee (France)
Chairperson: Prof. Martine Gilard - France

Members:
Prof. Aleksander Ernst          Croatia
Dr Alfredo Galassi            Italy
Dr Andres Iniguez Romo        Spain
Dr Nicholas Curzen             United Kingdom
Prof. C. Kaiser               Switzerland
Dr Knut Endresen              Norway
Prof. Christoph Naber         Germany
Dr Gregory Pavlides          Greece
Objectives

To develop the necessary tools to standardize the process of education and integrate this process in a full Curriculum.
• Training consists in 3 modules

**Knowledge**
- ESC Textbook
- Guidelines
- Peer reviewed published data
- What data matter
- Power of judgement

**Skill**
- Mentor
- Practical supervision
- Perform

**Attitude Behaviour**
- Patients
- Team
- Other specialists
- Referring MD
- Research & meeting
Training programme

• Practical skills
  – Procedural logbook:
    • recorded of the cath lab procedures,
    • description (complexity, device, complications), elective, urgent or emergency case.
    • Type of device and complications encountered
  – Practical skills assessment: Directly Observed Procedures (DOPs)

200 procedures as first or only operator, from which one third emergency or ACS procedures
Training programme

– Division of the curriculum in 4 steps over 2 y.
– Each step should include the 3 modules
– Questions for all topics will be made available on the website for self-assessment allowing the trainee to confirm his understanding of the main issues involved.
Key to success

E-Platform!

Procedures logbook example
Development of the educational material and practical steps towards building a web platform at the European Heart House

Dr L. Goncalves, Chair EAPCI Education Committee (Portugal)
EAPCI Educational Committee (2009-2011)

Chairperson: Dr Lino Goncalves - Portugal
Co-chairperson: Dr Ulf Jensen - Sweden

Members:
Prof. Jan Vojacek Czech republic
Prof. Goran Stankovic Serbia
Prof. Chris Vrints Belgium
Prof. Morris Mosseri Israël
Prof. György Szabo Hungary
Dr Raul Moreno Spain
Prof. Asim Oktay Ergene Turkey
Dr. Maciej Lesiak Poland
Dr Marco Zimarino Italy
EAPCI Educational Committee

Goals

• Produce Educational Materials & MCQs

• Support the EAPCI Training Programme
EAPCI Educational Committee

Goals

• Produce Educational Materials & MCQs

• Support the EAPCI Training Programme
EAPCI Educational Materials & MCQs

- CME courses.
- CME papers.
- Distance learning CME products (internet-based).
- Case-based learning.
- Virtual reality.
1. Cardiovascular anatomy and physiology.

2. Vascular biology and pathology.

3. Pathophysiology (with clinical applications: intracoronary imaging, QCA…).

4. Pharmacology.

5. Radiology imaging and safe use of radiation.


7. Interventional device design and performance.

8. Clinical management and strategy, pre- and post procedure.

EAPCI Educational Committee

Goals

• Produce Educational Materials & MCQs

• Support the EAPCI Training Programme
EAPCI Training Programme
- The Structure -

Knowledge Assessment
- Core Syllabus
- Core Curriculum
- Knowledge Content
- Summative/Formative Process/MCQs

Practical Skills Assessment
- E-logbook
- DOPs
- Lab Accreditation

Assessment of Professionalism
- Academic Achievements
- Research
- Other methods

Upon satisfactory completion
Training is accomplished
ESC Education on-line Project for Sub-specialities
- A modular Approach -

The more advanced sub-specialties may want to use all these modules. Other sub-specialties may want to use only some of these modules.
ESC Education on-line Project for Sub-specialities - Next Steps

• Road Map & Tender Process
  ✔  – End April: specification (RFP) document out to contenders
  – End of May: contenders send responses in
  – Early June: first short-list
  – Mid June: final selection
  – End June ESC Board Meeting: decision

• Heart House reorganisation

• Business Model  – to be developed
Cardiac Catheterization
Interventions
European Statistics 2007 / 2008

Bernhard Meier (Switzerland)
Cardiac Catheterization Interventions,
European Statistics 2007 / 2008

Complete or usable* data for

Austria, Belgium, Bosnia/Herzegovina, Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Irish Republic*, Italy, Latvia, Lithuania, Luxembourg, Netherlands*, Norway, Poland, Portugal, Macedonia* Romania, Serbia, Slovenia, Spain, Sweden, Switzerland, United Kingdom

→ 515 mio inhabitants
→ 600 catheterization laboratories
→ 10 PCI operators per mio inhabitants

No data for

Albania, Belarus, Denmark, Moldova, Slovak Republic, Turkey

→ 100 mio inhabitants

Affiliated to EAPCI

Algeria, Armenia, Egypt, Georgia, Israel, Lebanon, Libya, Morocco, Tunisia

Tunisia (10 mio) and Israel (7 mio) provided data
Coronary angiograms 1992 - 2010

Number of procedures in thousands

Observed: 684  757  923  1023  1199  1247  1134  1417  1637  1806  1902  1993  2186  2299  2481  2566  2628

Predicted: 659  750  847  949  1058  1172  1293  1419  1552  1691  1835  1986  2143  2306  2475  2650  2831  3019  3212

R² = 0.977

* Forecast based on data 1992 - 2005
PCI and stenting 1992 - 2010

Number of procedures in thousands

- PCI-Observed
- PCI-Predicted
- Stenting-Observed
- Stenting-Predicted

* Forecast based on data 1992 - 2005

R²=0.989 *

R²=0.991 *
France
Coronary angiographies and PCI

Forecast 2010 (based on data 1991 - 2008)

<table>
<thead>
<tr>
<th>Procedure</th>
<th>Number</th>
<th>PCI-ISR (=10,065)</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Angiograms</td>
<td>265,800</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PCI</td>
<td>125,816</td>
<td></td>
<td>8%</td>
</tr>
<tr>
<td>Stent</td>
<td>119,718</td>
<td>DES</td>
<td>54%</td>
</tr>
</tbody>
</table>

R² = 0.99
PCI Substrata 1992 - 2008

PCI for acute MI  Multivessel PCI  Ad hoc PCI  Total PCI
Multivessel PCI (in 1 Session)
(Registry of the European Society of Cardiology)
Non-coronary interventions 2005 - 2008

- Alcohol ablation for hypertrophic obstruct. CM
- Aortic valvulo-plasty
- PDA closure
- ASD closure
- Coartaction angioplasty
- Mitral valvulo-plasty
- Pulmonary valvulo-plasty
- PFO closure
- VSD closure
The ESC TAVI Registry: Role of EAPCI & National Societies

Prof C. Di Mario, EAPCI President (UK)
Original EuroHeart Survey Program

• In 1999 the ESC implemented an international clinical research programme, Euro Heart Survey
• Data collected allowed assessment of the adherence to ESC guidelines and highlighted differences in clinical practice in Europe possibly leading to differences in outcome
• Specific expertise developed at the Heart House to implement and manage web-based databases
BENCHMARKING FOR QUALITY CONTROL

PERCUTANEOUS CORONARY INTERVENTIONS (2005/2006)

PCI: Use of stents

Inclusion: ESC Member Countries
Exclusion: ---
Analysis: Hospital DE9 vs. other hospitals

<table>
<thead>
<tr>
<th>Number of patients</th>
<th>Hospital DE9</th>
<th>Other hospitals</th>
<th>OR (95%-CI)*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>175 (1.3%)</td>
<td>12977 (98.7%)</td>
<td></td>
</tr>
<tr>
<td>Stent Implantation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No stent</td>
<td>14.3% (25/175)</td>
<td>6.4% (826/12976)</td>
<td></td>
</tr>
<tr>
<td>1 stent</td>
<td>75.4% (132/175)</td>
<td>67.3% (8739/12976)</td>
<td></td>
</tr>
<tr>
<td>2 stents</td>
<td>9.1% (16/175)</td>
<td>19.7% (2550/12976)</td>
<td></td>
</tr>
<tr>
<td>At least 3 stents</td>
<td>1.1% (2/175)</td>
<td>6.6% (881/12976)</td>
<td></td>
</tr>
<tr>
<td>Direct stenting</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-drug eluting stent</td>
<td>66.9% (117/175)</td>
<td>55.1% (7144/12977)</td>
<td></td>
</tr>
<tr>
<td>Bare metal stent</td>
<td>66.9% (117/175)</td>
<td>55.1% (7144/12977)</td>
<td></td>
</tr>
<tr>
<td>Coated stent</td>
<td>0.0% (0/175)</td>
<td>1.7% (218/12977)</td>
<td></td>
</tr>
<tr>
<td>Drug eluting stent</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cypher</td>
<td>20.6% (36/175)</td>
<td>41.8% (5424/12977)</td>
<td></td>
</tr>
<tr>
<td>Taxus</td>
<td>22.2% (8/36)</td>
<td>55.4% (2006/5249)</td>
<td></td>
</tr>
<tr>
<td>Endeavor (TM)</td>
<td>77.6% (26/36)</td>
<td>39.0% (2049/5249)</td>
<td></td>
</tr>
<tr>
<td>Trial stent</td>
<td>0.0% (0/36)</td>
<td>3.8% (197/5249)</td>
<td></td>
</tr>
<tr>
<td>Other stent</td>
<td>0.0% (0/36)</td>
<td>4.4% (230/5249)</td>
<td></td>
</tr>
<tr>
<td>Maximal length of stent</td>
<td>0.6% (1/175)</td>
<td>0.6% (74/12977)</td>
<td></td>
</tr>
<tr>
<td>0 - 10 mm</td>
<td>19.3% (29/150)</td>
<td>0.2% (533/12120)</td>
<td></td>
</tr>
<tr>
<td>&gt;10 - 15 mm</td>
<td>19.3% (29/150)</td>
<td>24.0% (2911/12120)</td>
<td></td>
</tr>
<tr>
<td>&gt;15 - 20 mm</td>
<td>44.0% (66/150)</td>
<td>32.6% (3955/12120)</td>
<td></td>
</tr>
<tr>
<td>&gt;20 - 30 mm</td>
<td>9.3% (14/150)</td>
<td>25.9% (3139/12120)</td>
<td></td>
</tr>
<tr>
<td>&gt;30 mm</td>
<td>8.0% (12/150)</td>
<td>12.2% (1480/12120)</td>
<td></td>
</tr>
</tbody>
</table>

© ESC, Euro Heart Survey Programme
Analysis provided by IHF, Ludwigshafen, Germany
Euro Heart Survey on PCI
June 2005- January 2006
13.152 pts ;
134 Centres, 39 ESC member countries
New EurObservational Research program

- Oversight Committee including ESC President and President Elect and led by L. Tavazzi, charismatic leader of the successful GISSI programs
- Financial support secured for the entire program with no direct dependence from sponsorship of individual registries
- Direct involvement of National Societies: National coordinator in the Steering/Writing Committee
- Statistical analysis performed at the Heart House under the leadership of A. Maggioni
<table>
<thead>
<tr>
<th></th>
<th>2009</th>
<th>2010</th>
<th>2011</th>
<th>2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>Heart Failure</td>
<td>Heart Failure</td>
<td>Heart Failure</td>
<td>Heart Failure</td>
<td>Heart Failure</td>
</tr>
<tr>
<td>Pregnancy in Cardiac Diseases?</td>
<td>Pregnancy in Cardiac Diseases?</td>
<td>Pregnancy in Cardiac Diseases?</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Percutaneous Valve</td>
<td>Percutaneous Valve</td>
<td>Percutaneous Valve</td>
<td>Percutaneous Valve</td>
<td></td>
</tr>
<tr>
<td>Angina/IHD?</td>
<td>Angina/IHD</td>
<td>Angina/IHD</td>
<td>Angina/IHD</td>
<td>Angina/IHD</td>
</tr>
<tr>
<td>ACS?</td>
<td>ACS</td>
<td>ACS</td>
<td>ACS</td>
<td></td>
</tr>
</tbody>
</table>
1st Meeting Executive Committee: Paris April 28th

Carlo Di Mario, UK (Chairman), ESC
Neal Moat, UK, EATCS
Bernhard Lung, France, ESC WG on Valve Disease
Gerhard Schuler, Germany, EAPCI
Pepe Zamorano, Spain, EAE
Ottavio Alfieri, Italy, ESC WG of Cardiovascular Surgery
Olaf Franzen, Germany, EAPCI
Susanna Price, UK, ESC WG Acute Cardiac Care
Luigi Tavazzi, ESC, Oversight Committee

Patrick Serruys. Chairman CEC, Netherlands
Aldo Maggioni, EHH, Statistical Analysis
<table>
<thead>
<tr>
<th>Country</th>
<th>2009 Pts/Centres</th>
<th>Existing Registries</th>
</tr>
</thead>
<tbody>
<tr>
<td>Germany</td>
<td>2000/50?</td>
<td>ALKK/Univ.</td>
</tr>
<tr>
<td>UK</td>
<td>504/26</td>
<td>National UK</td>
</tr>
<tr>
<td>France</td>
<td>244-350/16-33</td>
<td>French Nat.</td>
</tr>
<tr>
<td>Italy</td>
<td>1100/</td>
<td>Regional/Planned National</td>
</tr>
<tr>
<td>Spain</td>
<td>300</td>
<td>In development</td>
</tr>
</tbody>
</table>
EUR Observational Research Program
Sentinel Registry TCVT

• Approved CE Marked Devices
• 30 day safety/efficacy endpoint, min f-up 1 year
• Consecutive enrolment – automatic data transfer
• VARC definitions

Launch ESC Stockholm
Fellowship and Database of Training Centres

Prof M. Haude, Chair EAPCI Fellowship Programme
EAPCI Research & Training Grants 2010

Chairperson: Prof Michael Haude - Germany

Members:
- Dr K. Trusinskis - Latvia
- Dr L. Zarma - Romania
- Dr I. Piek - Netherlands
- Dr A. Banning - United Kingdom
- Prof. G. Di Sciascio - Italy
- Dr R. Gil - Poland
- Dr J. Antoni Gomez - Spain

- In 2010, EAPCI received 3 submissions for Research & 15 submissions for Training Grants
2010 Fellowship Sponsors

• Cordis (2 Grants sponsored)
• Abbott Vascular,
• Terumo,
• The Medicines Company,
• EAPCI
<table>
<thead>
<tr>
<th>From</th>
<th>To</th>
<th>Programme Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Charalampos</td>
<td>UK</td>
<td>Post-DES implantation. The potential role of local tetrahydrobiopterin deficiency.</td>
</tr>
<tr>
<td>Christos</td>
<td>Cyprus</td>
<td>PCI and TAVI</td>
</tr>
<tr>
<td>Karim EL</td>
<td>Egypt</td>
<td>Influence of TAVI on aortic stiffness at 3 and 6 months post-procedure. Correlation with improvement in left ventricular function indices.</td>
</tr>
<tr>
<td>Amir-Ali FASSA</td>
<td>Switzerland</td>
<td>Post Doctorate Training Program in Interventional Cardiology</td>
</tr>
<tr>
<td>Timothy LOCKIE</td>
<td>UK</td>
<td>Assessment of coronary microvascular dysfunction by integrating wave intensity analysis after flow mediated dilation in response to metabolic stimulation (pacing) in patients with impaired glycaemic control.</td>
</tr>
<tr>
<td>Eliano NAVARESE</td>
<td>Italy</td>
<td>Training in advanced Interventional Cardiology</td>
</tr>
</tbody>
</table>

The EAPCI Fellowship Committee is in process of creating a list with updated information on centres willing to train fellows. Information will be made available on EAPCI website.
EAPCI Grants application procedure

• 12- month of training in an ESC Member country
  • Starting between May and December
  • Open to EAPCI Members from ESC Member countries < 36 years old
  • 24,000€ / year

• Deadline for application: 15 January 2011

• Results of selection process: end March
Criteria for endorsement of congresses and other scientific activities

Dr M. Sabate, Co-Chair EAPCI Clinical Research Committee
Already endorsed by EAPCI...

Books

CTO Club Congress

OCT paper

European Heart Journal

CardioPulse: in beat with the cardiovascular world

Expert review document on methodology, terminology, and clinical applications of optical coherence tomography: physical principles, methodology of image acquisition, and clinical application for assessment of coronary arteries and atherosclerosis
Endorsement by EAPCI

• Approval process for each request

• General rules:
  – No Competition with EuroPCR and ESC Annual Congress
  – High-level scientific content, free of bias
  – Course / event / educational material in English (or translation in English available) except for the annual meeting of Interventional WGs
  – Recognized educational and scientific value upon the EAPCI core curriculum
  – EBAC Accreditation strongly encouraged
  – Product not developed by industry (for educational materials)
  – Educational Material that may seek to support or to give credit to: Text (book, journal), Videoconference, Video, CD-ROM / DVD, Internet (web-based course), scientific publications
Endorsement by EAPCI

“Scientific programme / Educational material endorsed by EAPCI, a Registered branch of the European Society of Cardiology”

No logistical nor financial support provided by EAPCI

- **Option 1: Meets the prerequisites**
  - EAPCI involvement in the preparation
  - For meetings:
    - participation of at least one EAPCI Board Member or Committee at the opening and/or closing to present the EAPCI
    - Involvement of at least one EAPCI Board Member or Committee in Lectures

- **Option 2: Meets the prerequisites**
  - Meeting organised or educational material prepared in the field of interventional cardiology by a National Society and/or a National Working Group (although a meeting organised by a NS and/or a WG would automatically qualify for endorsement by EAPCI, a formal request of endorsement should be submitted).
Contribution of EAPCI to the Interventional programme at ESC Congress

Dr D. Dudek, Chair EAPCI Scientific Programme
EAPCI Scientific Committee 2009-2011

- Chairperson: Dr Dariusz Dudek - Poland
- Co-chairperson: Dr Marco Roffi - Switzerland

Members:
- Prof. Gerald Werner - Germany
- Dr Zbigniew Siudak - Poland
- Prof. Giuseppe De Luca - Italy
- Dr Thierry Lefevre - France
- Prof. Tony Gershlick - United Kingdom
- Prof. François Schiele - France
- Dr Alaide Chieffo - Italy
- Dr Fernando Alfonso - Spain
- Prof. Pavel Cervinka - Czech Republic
- Prof. Muzaffer Degertekin - Turkey
- Prof. José Baptista - Portugal
- Prof. Ivan Horvath - Hungary
- Dr Ioannis Iakovou - Greece
- Prof. Irene Lang - Austria
- Dr MarKo Noc - Slovenia
# Interventional Sessions – ESC Congress 2010

<table>
<thead>
<tr>
<th>Type</th>
<th>Process Type</th>
<th>Topic</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abstract Session</td>
<td>Abstract</td>
<td>05.05 - PCI / Stents: devices and technique (Spotlight 2010)</td>
<td>Interventional cardiology, new information from trials and registries</td>
</tr>
<tr>
<td>Abstract Session</td>
<td>Abstract</td>
<td>05.06 - PCI: procedural complications (Spotlight 2010)</td>
<td>Risk models to guide revascularization strategies</td>
</tr>
<tr>
<td>Abstract Session</td>
<td>Abstract</td>
<td>05.06 - PCI: procedural complications (Spotlight 2010)</td>
<td>Vascular access and bleeding complications during percutaneous cardiovascular interventions</td>
</tr>
<tr>
<td>Abstract Session</td>
<td>Abstract</td>
<td>05.07 - PCI: lesion / patient subsets (Spotlight 2010)</td>
<td>Complex percutaneous coronary intervention</td>
</tr>
<tr>
<td>Abstract Session</td>
<td>Abstract</td>
<td>05.08 - PCI: longterm outcome (Spotlight 2010)</td>
<td>Coronary stenting: insights from long term follow up</td>
</tr>
<tr>
<td>Abstract Session</td>
<td>Abstract</td>
<td>05.09 - Non coronary cardiac interventions</td>
<td>Transcatheter aortic valve replacement: focus on technique and outcomes</td>
</tr>
<tr>
<td>Clinical Seminar</td>
<td></td>
<td></td>
<td>A journey through non cardiac transcatheter interventions</td>
</tr>
<tr>
<td>Debate Session</td>
<td></td>
<td></td>
<td>Advances in lower limb angioplasty</td>
</tr>
<tr>
<td>ESC Clinical Practice Guidelines</td>
<td></td>
<td></td>
<td>Decision making in percutaneous intervention: a global perspective</td>
</tr>
<tr>
<td>Featured Research</td>
<td></td>
<td></td>
<td>ESC/EACTS Guidelines on myocardial revascularisation</td>
</tr>
<tr>
<td>Focus II</td>
<td></td>
<td></td>
<td>State of the Art - An integrated approach to improve patient care during primary angioplasty</td>
</tr>
<tr>
<td>Focus II</td>
<td></td>
<td></td>
<td>Left main and multivessel revascularisation in 2010 - LIVE from Riga</td>
</tr>
<tr>
<td>Focus II</td>
<td></td>
<td></td>
<td>Complications during percutaneous cardiovascular interventions</td>
</tr>
<tr>
<td>Focus II</td>
<td></td>
<td></td>
<td>Highlights from EuroPCR 2010</td>
</tr>
<tr>
<td>Main Session</td>
<td></td>
<td></td>
<td>Drug-eluting stents: from revolution to evolution</td>
</tr>
<tr>
<td>Main Session</td>
<td></td>
<td></td>
<td>Treatment of stable coronary disease</td>
</tr>
<tr>
<td>Mini-Satellite Session</td>
<td></td>
<td></td>
<td>Diabetes and revascularization – state of the art 2010</td>
</tr>
<tr>
<td>Mini-Satellite Session</td>
<td></td>
<td></td>
<td>Sex differences in coronary artery disease: less doubts, more facts</td>
</tr>
<tr>
<td>Mini-Satellite Session</td>
<td></td>
<td></td>
<td>Individualized antiplatelet therapy: for who and why?</td>
</tr>
<tr>
<td>Named Lecture</td>
<td></td>
<td></td>
<td>ESC Andreas Gruentzig Lecture on Interventional Cardiology</td>
</tr>
<tr>
<td>Satellite Session</td>
<td></td>
<td></td>
<td>Do current surface coated stents provide an optimal level of safety?</td>
</tr>
<tr>
<td>Symposium</td>
<td></td>
<td></td>
<td>Safety and drug-eluting stents – 4 years later</td>
</tr>
<tr>
<td>Symposium</td>
<td></td>
<td></td>
<td>The best of the European Heart Journal: new frontiers in intervention</td>
</tr>
<tr>
<td>Symposium</td>
<td></td>
<td></td>
<td>Innovation in stent technology</td>
</tr>
<tr>
<td>Symposium</td>
<td>Pre-arranged</td>
<td>05.05 - PCI / Stents: devices and technique (Spotlight 2010)</td>
<td>Controversies in percutaneous coronary intervention - a young cardiologist’s perspective</td>
</tr>
<tr>
<td>Symposium</td>
<td>Pre-arranged</td>
<td>05.06 - PCI: procedural complications (Spotlight 2010)</td>
<td>Risk models to guide revascularization strategies</td>
</tr>
<tr>
<td>Symposium</td>
<td>Pre-arranged</td>
<td>05.06 - PCI: procedural complications (Spotlight 2010)</td>
<td>Vascular access and bleeding complications during percutaneous cardiovascular interventions</td>
</tr>
<tr>
<td>Symposium</td>
<td>Pre-arranged</td>
<td>05.07 - PCI: lesion / patient subsets (Spotlight 2010)</td>
<td>Complex percutaneous coronary intervention</td>
</tr>
<tr>
<td>Symposium</td>
<td>Pre-arranged</td>
<td>05.08 - PCI: longterm outcome (Spotlight 2010)</td>
<td>Coronary stenting: insights from long term follow up</td>
</tr>
<tr>
<td>Symposium</td>
<td>Pre-arranged</td>
<td>05.09 - Non coronary cardiac interventions</td>
<td>Transcatheter aortic valve replacement: focus on technique and outcomes</td>
</tr>
<tr>
<td>Symposium</td>
<td>Pre-arranged</td>
<td>05.09 - Non coronary cardiac interventions</td>
<td>Tips and tricks of transcatheter cardiovascular interventions: West versus East</td>
</tr>
<tr>
<td>Symposium</td>
<td>Pre-arranged</td>
<td>05.09 - Non coronary cardiac interventions</td>
<td>Cell therapy for chronic heart disease</td>
</tr>
</tbody>
</table>

- **Abstracts**: 7
- **Clinical Seminars**: 2
- **Debate**: 1
- **ESC Clinical Guidelines**: 1
- **Featured Research**: 1
- **Focus II**: 3
- **Main Session**: 2
- **Name Lecture**: 1
- **Special Session**: 1
- **Symposium**: 6
Main task: preparation of Interventional Content of ESC Congress

1) EAPCI members should submit proposals of sessions to the Committee by end August 2010
2) Committee merges and edits proposals according to ESC rules (SCOPE) by end September 2010
3) Too technical sessions not suitable for ESC Congress will proposed to EuroPCR Programme Committee

Further task:
Abstract and late breaking trial evaluation for EuroPCR course
• **5th European Interventional Cardiology Fellows Course, London 2010**
  Royal College of Physicians, London (UK)
  25-26 November 2010

• **3rd European Interventional Cardiology Fellows Course, Krakow 2010**
  Institute of Cardiology, Jagiellonian University Medical College, Krakow (PL)
  1-2 December 2010
EAPCI 2010-2011
Budget Update

Dr K. Niemela, EAPCI Treasurer
## EAPCI 2010-2011 Budget Update

<table>
<thead>
<tr>
<th></th>
<th>FY 09/10 Budget (€)</th>
<th>FY 09/10 Forecast (€)</th>
<th>FY 10/11 Budget (€)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Europa Contribution</td>
<td>262 500</td>
<td>262 500</td>
<td>300 000</td>
</tr>
<tr>
<td>Grants and donations</td>
<td>171 000</td>
<td>171 000</td>
<td>280 000</td>
</tr>
<tr>
<td>Sponsorship (SFL)</td>
<td>60 000</td>
<td>117 500</td>
<td>240 000</td>
</tr>
<tr>
<td>Internal transfer (PCI Registry)</td>
<td>70 000</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Total Income</strong></td>
<td><strong>563 500</strong></td>
<td><strong>551 000</strong></td>
<td><strong>820 000</strong></td>
</tr>
<tr>
<td>Board &amp; Committee running costs</td>
<td>104 440</td>
<td>71 020</td>
<td>130 000</td>
</tr>
<tr>
<td>Investment</td>
<td></td>
<td></td>
<td><strong>150 000</strong></td>
</tr>
<tr>
<td>Stent for Life</td>
<td>62 000</td>
<td>106 690</td>
<td>224 000</td>
</tr>
<tr>
<td>Training &amp; Education</td>
<td>171 000</td>
<td>171 000</td>
<td>260 000</td>
</tr>
<tr>
<td>Advertising</td>
<td>7 600</td>
<td>4 800</td>
<td>9 000</td>
</tr>
<tr>
<td>Association Management costs</td>
<td>80 000</td>
<td>80 000</td>
<td>80 000</td>
</tr>
<tr>
<td>Internal transfer</td>
<td>1 500</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Miscellaneous</td>
<td>2 500</td>
<td>255</td>
<td>28 000</td>
</tr>
<tr>
<td><strong>Total Expenses</strong></td>
<td><strong>427 540</strong></td>
<td><strong>435 265</strong></td>
<td><strong>881 000</strong></td>
</tr>
<tr>
<td><strong>Net result</strong></td>
<td><strong>135 960</strong></td>
<td><strong>115 735</strong></td>
<td><strong>- 61 000</strong></td>
</tr>
</tbody>
</table>

- **5 grants + educational grant Fellows Course**
- Certification platform + registry database
- Grants + Fellows Course
- **7 grants**
- **150 000**
Stent for Life: promoting primary angioplasty in Europe

Prof. P. Widimsky
on behalf of the
Stent for Life Executive Board & Steering Committee
“Stent 4 Life”
Targeting PCI at all who will benefit the most
A joint project between EAPCI, Euro-PCR, EUCOMED and the ESC Working Group on Acute Cardiac Care

Petr Widimsky¹, Jean Fajadet², Nicolas Danchin³, William Wijns⁴*

1. Co-Chairman Stent 4 Life, ESC Practice Guidelines Committee, Cardiocenter, Charles University & University Hospital Kralovske Vinohrady, Prague, Czech Republic; 2. EAPCI and EuroPCR Board member, Clinique Pasteur, Toulouse, France; 3. Chairman of the ESC Working Group on Acute Cardiac Care, Hospital Européen Georges-Pompidou, Broussais-HEGP, Paris, France; 4. EAPCI President, Chairman of the ESC European Relations Committee, Cardiovascular Center, Aalst, Belgium
SFL Executive Board

- Petr Widimský, SFL Co-Chairman
- Jean Fajadet, SFL Co-Chairman
- William Wijns, EAPCI past-president
- Carlo di Mario, EAPCI president
- Nicolas Danchin, ESC WG ACC chairman
- Steen D. Kristensen, ESC vice-president

- Zuzana Kaifoszová – Project Manager
- Marielle de la Torre - Secretary
SfL partners

- Abbott Vascular
- Biotronik
- Boston Scientific
- Cordis Johnson & Johnson
- Eli Lilly
- IHT — Cordynamics
- Medtronic
- Philips Healthcare
- Terumo
- The Medicines Company
Reperfusion therapy for ST elevation acute myocardial infarction in Europe: description of the current situation in 30 countries

Petr Widimsky*, William Wijns, Jean Fajadet, Mark de Belder, Jiri Knot, Lars Aaberge, George Andrikopoulos, Jose Antonio Baz, Amadeo Betriu, Marc Claeys, Nicholas Danchin, Slaveyko Djambazov, Paul Erne, Juha Hartikainen, Kurt Huber, Petr Kala, Milka Klinčeva, Steen Dalby Kristensen, Peter Ludman, Josephina Mauri Ferre, Bela Merkely, Davor Miličić, Joao Morais, Marko Noč, Grzegorz Opolski, Miodrag Ostojić, Dragana Radovanović, Stefano De Servi, Ulf Stenestrand, Martin Studenčan, Marco Tubaro, Zorana Vasiljević, Franz Weidinger, Adam Witkowski, and Uwe Zeymer on behalf of the European Association for Percutaneous Cardiovascular Interventions†

Cardiocenter, 3rd Faculty of Medicine, Charles University Prague, Czech Republic

Received 15 March 2009; revised 20 August 2009; accepted 5 October 2009; online publish-ahead-of-print 19 November 2009
Annual incidence of p-PCI

- ≥600 p-PCI / million / year
- 400-599 p-PCI / million / year
- 200-399 p-PCI / million / year
- <200 p-PCI / million / year
- Data not known
How to set up an effective national primary angioplasty network: lessons learned from five European countries

Jiri Knot1*, MD; Petr Widimsky1, MD, DrSc, FESC; William Wijns2, MD, PhD, FESC; Ulf Stenestrand3, MD, PhD; Steen Dalby Kristensen4, MD, PhD, FESC; Arnoud van’t Hof5, MD, PhD; Franz Weidinger6, MD, PhD, FESC; Magnus Janson7, MD, PhD; Bjarne Linde Nörgaard7, MD, PhD; Jacob Thorsted Soerensen4, MD; Henri van de Wetering8, MA, ANP; Kristian Thygesen9, MD, DMSc, FESC; Per-Adolf Bergsten10, MD; Christofer Digerfeldt11, MD; Adriaan Potgieter12, MD; Nadav Tomer13, BSc, MBA; Jean Fajadet14, MD, PhD, FESC on behalf of the “Stent for Life” Initiative#

1. Cardiocenter, Department of Cardiology, 3rd Faculty of Medicine Charles University and University Hospital Kralovske Vinohrady, Prague, Czech Republic; 2. Cardiovascular Center Aalst, Aalst, Belgium; 3. Department of Cardiology, University Hospital, Linköping, Sweden; 4. Department of Cardiology, Aarhus University Hospital Skejby, Århus, Denmark; 5. Department of Cardiology, Isala Klinieken, locatie Wezenlanden, Zwolle, The Netherlands; 6. Department of Medicine II, Hospital Rudolfstiftung, Vienna, Austria; 7. Department of Cardiology, Vejle Hospital, Vejle, Denmark; 8. Department of Cardiology, Isala Klinieken and Regionale Ambulance Voorziening IJsselland, Zwolle, The Netherlands; 9. Department of Medicine and Cardiology, Aarhus University Hospital, Aarhus C, Denmark; 10. Medical Officer EMS, Österåtland, Linköping, Sweden; 11. Department of Internal Medicine, Vrinnevi Hospital, Norrköping, Sweden; 12. Abbott Vascular, Brussels, Belgium; 13. Cordis EMEA, Johnson & Johnson, Waterloo Belgium; 14. Department of Cardiology, Clinique Pasteur, Toulouse, France

* “Stent for Life” Initiative is a project jointly organised by the European Association of Percutaneous Cardiovascular Interventions (EAPCI) and EuroPCR, supported by EUCOMED and the ESC Working Group on Acute Cardiac Care. Project Steering Committee: Petr Widimsky, Jean Fajadet, Adriaan Potgieter, Nadav Tomer, William Wijns and Nicolas Danchin.
The authors have no conflict of interest to declare.
3rd phase (2010-12): To improve the situation in countries performing <250 p-PCI/ million/ year

FR, ES, BG, SRB, TR, GR
The ultimate SfL goal:

- ≥600 p-PCI / million / year
- 400-599 p-PCI / million / year
- 200-399 p-PCI / million / year
- <200 p-PCI / million / year
- Data not known
Hospital Volume and 30-Day Mortality for Three Common Medical Conditions

Joseph S. Ross, M.D., M.H.S., Sharon-Lise T. Normand, Ph.D., Yun Wang, Ph.D., Dennis T. Ko, M.D., Jersey Chen, M.D., Elizabeth E. Drye, M.D., Patricia S. Keen, Ph.D., Judith H. Lichtman, Ph.D., M.P.H., Héctor Bueno, M.D., Ph.D., Geoffrey C. Schreiner, B.S., and Harlan M. Krumholz, M.D.
Hospitals treating >200 MIs / year = mortality <5%,
100 MIs / year = mortality cca 8%,
20 MIs / year = mortality cca 20% !!!
EuroIntervention Update

Prof. P.W. Serruys, EuroIntervention Journal Editor-in-Chief
Q&A
Don’t miss the next EAPCI General Assembly
Monday 30 August, 15:30-16:30, Room 4

See you at ESC Congress in Stockholm
28 August – 2 September....